Deferoxamine reduces cold-ischemic renal injury in a syngeneic kidney transplant model.

Huang H, He Z, Roberts LJ, Salahudeen AK
Am J Transplant. 2003 3 (12): 1531-7

PMID: 14629283 · DOI:10.1046/j.1600-6135.2003.00264.x

In cell-culture models, addition of deferoxamine (DFO) to University of Wisconsin Solution (UW solution) reduces cold-storage injury. The efficacy of DFO was therefore tested in a kidney transplantation model employing inbred Wistar Furth rats. Donor left kidneys, cold stored for 18 h in UW solution with or without 0.125 mM or 0.625 mM DFO were transplanted to the recipients' left renal fosse. Deferoxamine dose-dependently and significantly increased glomerular filtration rate (GFR) and renal blood flow (RBF), and suppressed renal F2-isoprostanes (vasoactive lipid peroxidation products) and apoptotic and necrotic injury 3 days post-transplantation. In a second set of similar experiments, the remaining native kidneys of the recipient rats were removed on day 7 of transplantation. Transplanted kidneys' function assessed by serum creatinine was 75% higher in the cold-stored transplanted kidneys treated with DFO compared with untreated kidneys. Moreover, the DFO treatment was attended by a significant reduction in apoptotic and necrotic tubular injury. Thus, our consistent findings from two sets of studies in a transplant model suggest that a simple strategy of including DFO in the cold-storage solution reduces cold ischemia-associated renal transplant damage and improves renal function. Our findings have potentially important ramifications for cold preservation of kidneys, and possibly other organs, in clinical transplantation.

MeSH Terms (12)

Animals Cold Temperature Deferoxamine Dose-Response Relationship, Drug Iron Chelating Agents Ischemia Kidney Kidney Transplantation Male Rats Rats, Wistar Transplantation, Isogeneic

Connections (1)

This publication is referenced by other Labnodes entities: